• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Spyre Therapeutics, Inc. - Common Stock (NQ:SYRE)

    107.36 +0.71 (+0.67%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Spyre Therapeutics, Inc. - Common Stock

    < Previous 1 2 Next >
    What's going on in today's after hours session ↗
    Via Chartmill
    News headline image
    Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre's CEO Sold Stock, but Kept 567,000 Shares. Here's What Long-Term Investors Should Know ↗
    This disposition follows a staggering 500% one-year stock surge. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    A Spyre Executive Sold Stock After a 500% Run. Here's What Long-Term Investors Should Know ↗
    This sale was executed under a pre-arranged plan as the stock posted a staggering return over 12 months. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Participate in Upcoming June Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares ↗
    Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases. 
    Via The Motley Fool
    News headline image
    Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares ↗
    Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Has a June 30 FDA Catalyst. A Fund Just Cut Its Stake by $7 Million ↗
    Viridian Therapeutics develops monoclonal antibody therapies targeting serious diseases, with a primary focus on thyroid eye disease. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    These stocks are gapping in today's session ↗
    Let's have a look at what is happening on the US markets on Monday. Below you can find the gap up and gap down stocks in today's session. 
    Via Chartmill
    News headline image
    Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears ↗
    This biotech innovator in antibody therapies for IBD reported a notable insider sale amid ongoing preclinical development efforts. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗
    Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health. 
    Via The Motley Fool
    News headline image
    What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗
    This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    VR Adviser Adds Over 1 Million Savara Shares ↗
    This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics to Participate in Upcoming March Investor Conferences
    From Spyre Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
    Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
    Via The Motley Fool
    News headline image
    Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
    Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
    Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
    Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in biopharma. 
    Via The Motley Fool
    Topics Regulatory Compliance
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.